CIT - citron rho-interacting serine/threonine kinase Gene

中文名称：Citron rho 相互作用丝氨酸/苏氨酸激酶

种属: Homo sapiens

同用名: CITK; CRIK; STK21; MCPH17

基因 ID: 11113 | 基因类型: protein coding

关于 CIT

Cytogenetic location: 12q24.23 Genomic coordinates (GRCh38): 12:119,685,791-119,877,320 (from NCBI)

This gene has 40 transcripts (splice variants), 272 orthologues, 5 paralogues and is associated with 3 phenotypes. Broad expression in brain (RPKM 9.1), testis (RPKM 3.2) and 18 other tissues.

功能概要

该基因编码一种在细胞分裂中起作用的丝氨酸/苏氨酸蛋白激酶。与驱动蛋白 KIF14 一起，该蛋白定位于中央纺锤体和中体，并发挥促进有效胞质分裂的作用。这种蛋白质参与中枢神经系统发育。该基因的多态性与双相情感障碍和精神分裂症的风险有关。可变剪接导致多个转录本变体。[RefSeq 提供，2011 年 8 月]

This gene encodes a serine/threonine-protein kinase that functions in cell division. Together with the Kinesin KIF14, this protein localizes to the central spindle and midbody, and functions to promote efficient cytokinesis. This protein is involved in central nervous system development. Polymorphisms in this gene are associated with bipolar disorder and risk for schizophrenia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2011]

CIT 基因产物(2)

mRNA	Protein	Name
NM_001206999.2	NP_001193928.1	citron Rho-interacting kinase isoform 1
NM_007174.3	NP_009105.1	citron Rho-interacting kinase isoform 2

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables PDZ domain binding	IDA IDA: 通过直接分析推断	17474715	GOA
enables protein binding	IPI IPI: 通过物理相互作用推断	16431929	GOA
enables protein kinase binding	IPI IPI: 通过物理相互作用推断	30865227	GOA
enables protein serine/threonine kinase inhibitor activity	IDA IDA: 通过直接分析推断	30865227	GOA
enables scaffold protein binding	IDA IDA: 通过直接分析推断	17474715	GOA
enables transcription coactivator binding	IPI IPI: 通过物理相互作用推断	30865227	GOA

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in mitotic cytokinesis	IMP IMP: 通过突变表型推断	16236794	GOA
involved in negative regulation of hippo signaling	IMP IMP: 通过突变表型推断	30865227	GOA
involved in neuron apoptotic process	IMP IMP: 通过突变表型推断	27453578	GOA
involved in positive regulation of cytokinesis	IMP IMP: 通过突变表型推断	16431929	GOA

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in cytosol	IDA IDA: 通过直接分析推断	30865227	GOA

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

CIT 蛋白结构

Pkinase

Pkinase_C

CNH

0
400
800
1200
1600
2027 a.a.

蛋白主名

其他名称

citron Rho-interacting kinase

citron (rho-interacting, serine/threonine kinase 21)

关联疾病

疾病名称

别名

Microcephaly 17, Primary, Autosomal Recessive

MCPH17

Primary Autosomal Recessive Microcephaly 17

Primary Autosomal Recessive Microcephaly

Autosomal Recessive Primary Microcephaly	Mcph
True Microcephaly	Microcephalia Vera
Microcephaly Vera	Microcephaly Primary Hereditary
Microcephaly, Primary, Autosomal Recessive	Primary Microcephaly

Microcephaly 6, Primary, Autosomal Recessive

MCPH6	Primary Autosomal Recessive Microcephaly 6
Microcephaly, Primary Autosomal Recessive, 6	Microcephaly, Type 6, Primary, Autosomal Recessive

Cerebellar Hypoplasia

Microcephaly

Microencephaly	Microcephalus
Microcephalic	Nanocephaly
Congenital Microcephaly	Brain Hypoplasia
Brain Nondevelopment	Cephalic Hypoplasia
Undeveloped Cerebrum	Undeveloped Brain
Micrencephalon	Micrencephaly

Bipolar Disorder

Bipolar Depression	Manic Disorder
Depression, Bipolar	Bipolar Disorder Manic Phase
Depressive-Manic Psych.	Manic Bipolar Affective Disorder
Manic Bipolar I Disorder	Manic Depression
Manic Depressive Disorder	Mixed Bipolar Disorder
Bipolar Affective Disorder	Bipolar Affective Psychosis
Bipolar Spectrum Disorder	Manic Depressive Illness
Depression Bipolar	Bipolar Disorder, Mixed
Major Affective Disorder	Major Affective Disorder 1
Major Affective Disorder 2

Microcephaly 5, Primary, Autosomal Recessive

MCPH5	Primary Autosomal Recessive Microcephaly 5
Microcephaly Primary Autosomal Recessive 5 With Simplified Gyral Pattern	Microcephaly, Primary Autosomal Recessive, 5

Schizophrenia

SCZD	Schizophrenia With Or Without An Affective Disorder
Schizophrenia 12	Schizophrenia, Susceptibility To
Schizophrenia-1	Dementia Praecox
Schizophrenia 1

Lissencephaly

Pachygyria	Broad Gyri Of Cerebrum
Large Gyri Of Cerebrum	Macrogyria

Primary Microcephaly

True Microcephaly

Microcephaly, Primary

Congenital Nervous System Abnormality

Congenital Neurologic Anomaly

Congenital Nervous System Disorder

疾病名称	别名
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

相关产品

Clinical Phase

生物活性分子 (2)

目录号	产品名	作用方式	纯度	Phase
HY-160441	MC-Val-Cit-PAB-Ispinesib	Inhibitor	99.85%	Phase 3
HY-141601	Telisotuzumab vedotin	Inhibitor	99.90%	Phase 2

抗体抑制剂 (1)

目录号	产品名	作用方式	纯度	Phase
HY-P99612	Farletuzumab ecteribulin		98.10%	Phase 2

Pre-clinical Phase

生物活性分子 (157)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-15575	VcMMAE	Inhibitor	99.97%	否
HY-20336	Mc-Val-Cit-PABC-PNP		98.89%	否
HY-100374	Val-Cit-PAB-MMAE		99.83%	否
HY-112786	MC-Val-Cit-PAB-MMAF		98.16%	否
HY-78738	MC-Val-Cit-PAB		99.55%	否
HY-145929	MC-Val-Cit-PAB-Exatecan	Inhibitor	99.57%	否
HY-12362	Val-cit-PAB-OH		99.64%	否
HY-41189	Fmoc-Val-Cit-PAB-PNP		98.99%	否
HY-131296	5-A-RU-PABC-Val-Cit-Fmoc		98.85%	否
HY-19318	Fmoc-Val-Cit-PAB		99.39%	否
HY-130990	DBCO-PEG4-Val-Cit-PAB-MMAF		99.99%	否
HY-139642	Mal-(CH2)5-Val-Cit-PAB-Eribulin		99.82%	否
HY-141154	Amino-PEG4-Val-Cit-PAB-MMAE		99.93%	否
HY-141156	Mal-PEG8-Val-Cit-PAB-MMAE		99.67%	否
HY-128904	MC-Val-Cit-PAB-duocarmycin chloride		98.77%	否
HY-100566	SuO-Val-Cit-PAB-MMAE		99.24%	否
HY-141155	endo-BCN-PEG4-Val-Cit-PAB-MMAE		99.95%	否
HY-100567	MAL-di-EG-Val-Cit-PAB-MMAE		98.04%	否
HY-100115	TA-02	Inhibitor	99.85%	否
HY-141142	Boc-Val-Cit-PAB-PNP		99.55%	否
HY-15575G	VcMMAE (GMP)		/	否
HY-140150	Azido-PEG3-Val-Cit-PAB-PNP		99.09%	否
HY-130989	SuO-Glu-Val-Cit-PAB-MMAE		99.20%	否
HY-136154	Fmoc-Glu-(Boc)-Val-Cit-PAB-PNP		96.67%	否
HY-153263	(Aminooxy)acetamide-Val-Cit-PAB-MMAE		97.01%	否
HY-148875	Py-MAA-Val-Cit-PAB-MMAE		99.78%	否
HY-130937	DBCO-Val-Cit-PABC-PNP		96.54%	否
HY-W008064	Fmoc-Cit-OH		99.32%	否
HY-19812	Acetylene-linker-Val-Cit-PABC-MMAE		95.21%	否
HY-141833	Bi-Mc-VC-PAB-MMAE		99.78%	否
HY-128902	MC-Val-Cit-PAB-vinblastine		92.87%	否
HY-147286	Ac-Lys-Val-Cit-PABC-MMAE		99.99%	否
HY-W038702	Boc-Val-Cit-OH		≥98.0%	否
HY-153031	Val-Cit-PAB-Exatecan	Inhibitor	99.23%	否
HY-19813A	mDPR-Val-Cit-PAB-MMAE TFA		99.51%	否
HY-15742	Vc-MMAD	Inhibitor	99.96%	否
HY-140145	Mal-PEG4-Val-Cit-PAB-PNP		97.05%	否
HY-148245	OH-Glu-Val-Cit-PAB-MMAE		99.92%	否
HY-P4160	PDC31	Inhibitor	99.76%	否
HY-44177	Val-Cit-PAB-MMAF sodium		98.43%	否
HY-140147	Mal-amido-PEG2-Val-Cit-PAB-PNP		98.40%	否
HY-19811	Fmoc-Val-Cit-PAB-MMAE	Inhibitor	98.89%	否
HY-112099	Mc-Val-Cit-PAB-Cl		99.67%	否
HY-128903	MC-Val-Cit-PAB-carfilzomib iodide		96.58%	否
HY-130944	Mal-PEG1-Val-Cit-PABC-OH		95.01%	否
HY-139726	Mal-PEG4-Val-Cit-PAB-MMAE		98.64%	否
HY-140149	Azido-PEG4-Val-Cit-PAB-OH		≥98.0%	否
HY-155052A	PAD4-IN-2 TFA	Inhibitor	95.64%	否
HY-141860	PSMA-Val-Cit-PAB-MMAE	Inhibitor	99.52%	否
HY-140014	Val-Cit		99.38%	否
HY-141141	Boc-Val-Cit-PAB		99.99%	否
HY-W190943	Azido-PEG4-Val-Cit-PAB-MMAE		99.43%	否
HY-78736	Val-Cit-PAB-OSBT		99.55%	否
HY-126532	Fmoc-Val-Cit-PAB-Duocarmycin TM		99.44%	否
HY-128899	MC-Val-Cit-PAB-Auristatin E		96.97%	否
HY-130222	Mal-PEG2-Val-Cit-PAB-OH		99.49%	否
HY-138106	Fmoc-D-Cit-OH		/	否
HY-145489	Mal-PEG2-Val-Cit-PABA		98.91%	否
HY-15575S	VcMMAE-d8	Inhibitor	97.56%	否
HY-156758	Mal-PEG8-Val-Cit-PAB-MMAF		96.50%	否
HY-160774	Val-Cit-PABC-DOX	Inhibitor	95.06%	否
HY-160893	PSMA-Val-Cit-PAB-Azide		99.43%	否
HY-19697	Aminocaproyl-Val-Cit-PABC-MMAE		99.89%	否
HY-W591408	DBCO-Val-Cit-PAB-MMAE		98.33%	否
HY-153031A	Val-Cit-PAB-Exatecan TFA	Inhibitor	98.14%	否
HY-Z0922	(R,R)-MC-Val-Cit-PAB	Control	97.06%	否
HY-128906	MC-Val-Cit-PAB-Retapamulin		99.00%	否
HY-128909	MC-Val-Cit-PAB-rifabutin		95.33%	否
HY-145960	MC-Val-Cit-PAB-Amide-TLR7 agonist 4	Agonist	99.39%	否
HY-126672	Mal-PEG4-Val-Cit-PAB		98.87%	否
HY-128711	MAL-di-EG-Val-Cit-PAB-MMAF		98.56%	否
HY-128907	MC-Val-Cit-PAB-clindamycin		99.99%	否
HY-128908	MC-Val-Cit-PAB-Indibulin		95.82%	否
HY-130923	BCN-PEG1-Val-Cit-PABC-OH		/	否
HY-140143	Mal-PEG4-Val-Cit-PAB-OH		96.92%	否
HY-147286A	Ac-Lys-Val-Cit-PABC-MMAE formic		99.96%	否
HY-148871	Mc-Val-Cit-PAB-Gefitinib chloride		98.69%	否
HY-155052	PAD4-IN-2	Inhibitor	/	否
HY-19318A	Fmoc-Val-D-Cit-PAB		/	否
HY-19318B	Fmoc-D-Val-Cit-PAB		/	否
HY-19318C	Fmoc-D-Val-D-Cit-PAB		98.97%	否
HY-126492	Vat-Cit-PAB-Monomethyl Dolastatin 10		/	否
HY-128893	MC-Sq-Cit-PAB-Gefitinib		/	否
HY-128905	MC-Val-Cit-PAB-dimethylDNA31		/	否
HY-131156	Mal-PEG2-Val-Cit-PABA-PNP		96.82%	否
HY-101909	Val-Cit-PAB-MMAF		/	否
HY-100374G	Val-Cit-PAB-MMAE (GMP)		/	否
HY-111121	cBu-Cit-OH		/	否
HY-12362G	Val-cit-PAB-OH (GMP)		/	否
HY-126533	PDP-C1-Ph-Val-Cit		/	否
HY-126667	SC-Val-Cit-PAB		/	否
HY-126670	mDPR(Boc)-Val-Cit-PAB		/	否
HY-126671	Mal-Phe-C4-Val-Cit-PAB		/	否
HY-126674	Mal-Phe-C4-Val-Cit-PAB-DMEA		/	否
HY-126676	DBCO-(PEG2-Val-Cit-PAB)2		/	否
HY-128894	MC-Sq-Cit-PAB-Dolastatin10		/	否
HY-130922	BCN-PEG1-Val-Cit-OH		/	否
HY-130930	Acid-propionylamino-Val-Cit-OH		/	否
HY-130934	TCO-PEG1-Val-Cit-OH		/	否
HY-130935	DBCO-Val-Cit-OH		/	否
HY-130936	DBCO-Val-Cit-PABC-OH		/	否
HY-130966	TCO-PEG1-Val-Cit-PABC-OH		/	否
HY-132973	MC-Val-Cit-PAB-NH-C2-NH-Boc		≥95.0%	否
HY-133459	Mal-PEG1-Val-Cit-OH		/	否
HY-136034	Azido-PEG1-Val-Cit-OH		/	否
HY-136098	DBCO-PEG4-acetic-Val-Cit-PAB		98.21%	否
HY-136100	TCO-PEG1-Val-Cit-PABC-PNP		/	否
HY-136103	DBCO-PEG4-Propionic-Val-Cit-PAB		/	否
HY-136105	Azido-PEG1-Val-Cit-PABC-PNP		/	否
HY-136106	Fmoc-Gly3-Val-Cit-PAB		≥98.0%	否
HY-136108	Fmoc-Gly3-Val-Cit-PAB-PNP		/	否
HY-136137	Azide-PEG1-Val-Cit-PABC-OH		/	否
HY-140144	Mal-PEG1-Val-Cit-PAB-PNP		98.41%	否
HY-140146	Mal-amido-PEG2-Val-Cit-PAB-OH		/	否
HY-140148	Azido-PEG3-Val-Cit-PAB-OH		/	否
HY-141143	MC(C5)-Val-Cit		/	否
HY-141144	OPSS-Val-Cit-PAB-OH		/	否
HY-141145	OPSS-Val-Cit-PAB-PNP		/	否
HY-147021	MC-Val-D-Cit-PAB-PNP		/	否
HY-147021A	MC-D-Val-Cit-PAB-PNP		/	否
HY-148326	Glu(OtBu)-Val-Cit-PAB-OH		/	否
HY-151700	6-Azidohexanoyl-Val-Cit-PAB		/	否
HY-153236	Py-MAA-Val-Cit-PAB-DX8951		/	否
HY-153373	4A3-Cit		/	否
HY-156727	Val-Cit-PABC-Ahx-May		/	否
HY-156727A	Val-Cit-PABC-Ahx-May TFA		/	否
HY-156896	Val-Cit-amide-Cbz-N(Me)-Maytansine		97.92%	否
HY-156897	Val-Cit-amide-Ph-Maytansine		98.01%	否
HY-158135	Val-Cit-PAB-DEA-COOH		/	否
HY-158137	Val-Cit-PAB-DEA-Dxd		/	否
HY-160694	cBu-Cit-PROTAC BRD4 Degrader-5		/	否
HY-160756A	Val-Cit-Exatecan TFA		/	否
HY-164303	Val-Cit-PAB-DEA-Duo-DM	Inhibitor	/	否
HY-164309	DBCO-PEG3-Glu-Val-Cit-PABC-MMAE		/	否
HY-164310	TCO-PEG3-Glu-Val-Cit-PABC-MMAF	Inhibitor	/	否
HY-171159	MC-Val-Cit-PAB-Sunitinib		/	否
HY-19318G	Fmoc-Val-Cit-PAB (GMP)		/	否
HY-20336G	Mc-Val-Cit-PABC-PNP (GMP)		/	否
HY-78736G	Val-Cit-PAB-OSBT (GMP)		/	否
HY-78738G	MC-Val-Cit-PAB (GMP)		/	否
HY-P4007	[Pmp1,DTyr(OEt)2,Val4,Cit8] Vasopressin		/	否
HY-P4810	Polyphemusin II-Derived Peptide	Inhibitor	/	否
HY-P5372	Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2	Agonist	/	否
HY-P5836	Citrullinated LL-37 1cit	Inhibitor	/	否
HY-P5837	Citrullinated LL-37 2cit	Inhibitor	/	否
HY-P5838	Citrullinated LL-37 5cit	Inhibitor	/	否
HY-P5842	Citrullinated LL-37 3cit	Inhibitor	/	否
HY-P5843	Citrullinated LL-37 4cit	Inhibitor	/	否
HY-RS02727	CIT Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W016733	D-Citrulline		/	否
HY-151699	6-Azidohexanoyl-Val-Cit-PAB-PNP		/	否
HY-151709	N3-L-Cit-OH		/	否
HY-151709A	N3-L-Cit-OH (DCHA)		/	否
HY-151726	Azido-PEG(4)-Val-Cit-PAB-PNP		/	否
HY-164273	Azidoacetyl-Val-Cit-PAB-OH		/	否
HY-164275	Alkyne-Val-Cit-PAB-OH		/	否
HY-W591286	Alkyne-Val-Cit-PAB-PNP		/	否

抗体抑制剂 (1)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-164154	ADC Control Human IgG1-vcMMAF	Inhibitor	98.02%	否

直系同源

种属	基因名	来源	基因 ID
Rattus norvegicus	CIT	RGD	RGD:70878
Bos taurus	CIT	VGNC	VGNC:27375
Felis catus	CIT	VGNC	VGNC:80432
Mus musculus	CIT	MGD	MGI:105313
Macaca mulatta	CIT	VGNC	VGNC:71226
Canis familiaris	CIT	VGNC	VGNC:39282
Macaca fascicularis	CIT	NCBI	NCBI:102134813
Others	CIT	NCBI

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4